Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07545590

A Study of Eltrekibart (LY3041658) in Healthy Participants

The main purpose of this study is to evaluate how eltrekibart is absorbed by the body when it is given under the skin to healthy participants.

The study will last about 17 weeks.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Healthy

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Lilly Centre for Clinical Pharmacology

Singapore, 138623

Location status: Recruiting

Location contact

Greg Li

PRINCIPAL_INVESTIGATOR

CONTACT

+65 6413 9838

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation including medical history and physical examination
  • Have a minimum body weight of 45 kilograms (kg).
  • Have a body mass index (BMI) within the range of 18.5 to 28.5 kilograms per square meter (kg/m²), inclusive

Exclusion criteria

  • Have multiple severe allergies to prescription or nonprescription drugs
  • Are immunocompromised
  • Have had any of the following types of infection within 3 months prior to the screening visit:
  • Serious, that is, requiring hospitalization, or intravenous or equivalent oral antibiotic treatment
  • Opportunistic infections Note: Herpes zoster is considered active and ongoing until all vesicles are dry and crusted over
  • Chronic, that is, duration of symptoms, signs, or treatment of 6 weeks or longer, or
  • Recurring, including, but not limited to:
  • herpes simplex,
  • herpes zoster,
  • recurring cellulitis, or
  • chronic osteomyelitis.
  • Are currently pregnant or are intending to become pregnant or to breastfeed at any time in the study or within 16 weeks after receiving the single dose of study intervention.

Treatment and study plan

LY3041658

Drug

Administered SC

Other names: Eltrekibart

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658

    Time frame: Predose on Day 1 up to Day 85

  2. PK: Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3041658

    Time frame: Predose on Day 1 up to Day 85

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to Time t, Where t is the Last Time Point With a Measurable Concentration AUC(0-tlast) of LY3041658

    Time frame: Predose on Day 1 up to Day 85

Study contacts

Contact information is provided by the study sponsor or research team.

Physicians interested in becoming principal investigators please contact

CONTACT

[email protected]

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

[email protected]

1-317-615-4559

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and Tolerability of Two Formulations of Eltrekibart in Healthy Participants

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 22, 2026
Registry last updated
Jun 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.